Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 lot consistency, dose level, and booster phase 3 study in healthy participants aged 12 to 50 years
2021-005903-11Phase 3
- Sponsor
- BioNTech SE
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by BioNTech SE. Primary endpoint: Geometric Mean Ratio of SARS-CoV-2 full-length S-binding antibody levels between US lots.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005903-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005903-11.